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Abstract
Background
Brain tumours are recognised as one of the most difficult cancers to diagnose
because presenting symptoms, such as headache, cognitive symptoms, and seizures,
may be more commonly attributable to other, more benign conditions. Interventions to
reduce the time to diagnosis of brain tumours include national awareness initiatives,
expedited pathways, and protocols to diagnose brain tumours, based on a person's
presenting symptoms and signs; and interventions to reduce waiting times for brain
imaging pathways. If such interventions reduce the time to diagnosis, it may make it
less likely that people experience clinical deterioration, and different treatment options
may be available.
Objectives
To systematically evaluate evidence on the effectiveness of interventions that may
influence: symptomatic participants to present early (shortening the patient interval),
thresholds for primary care referral (shortening the primary care interval), and time to
imaging diagnosis (shortening the secondary care interval and diagnostic interval).
To produce a brief economic commentary, summarising the economic evaluations
relevant to these interventions.
Search methods
For evidence on effectiveness, we searched CENTRAL, MEDLINE, and Embase from
January 2000 to January 2020; Clinicaltrials.gov to May 2020, and conference
proceedings from 2014 to 2018. For economic evidence, we searched the UK National
Health Services Economic Evaluation Database from 2000 to December 2014.
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Selection criteria
We planned to include studies evaluating any active intervention that may influence the
diagnostic pathway, e.g. clinical guidelines, direct access imaging, public health
campaigns, educational initiatives, and other interventions that might lead to early
identification of primary brain tumours. We planned to include randomised and non-
randomised comparative studies. Included studies would include people of any age,
with a presentation that might suggest a brain tumour.
Data collection and analysis
Two review authors independently assessed titles identified by the search strategy, and
the full texts of potentially eligible studies. We resolved discrepancies through
discussion or, if required, by consulting another review author.
Main results
We did not identify any studies for inclusion in this review. We excluded 115 studies.
The main reason for exclusion of potentially eligible intervention studies was their study
design, due to a lack of control groups. We found no economic evidence to inform a
brief economic commentary on this topic.
Authors' conclusions
In this version of the review, we did not identify any studies that met the review
inclusion criteria for either effectiveness or cost-effectiveness. Therefore, there is no
evidence from good quality studies on the best strategies to reduce the time to
diagnosis of brain tumours, despite the prioritisation of research on early diagnosis by
the James Lind Alliance in 2015.
This review highlights the need for research in this area.
Plain language summary
How effective are initiatives that aim to
speed up the diagnosis of brain
tumours?
Why this question is important
 
A brain tumour is a group of cells in the brain that develop in an abnormal and
uncontrollable way. There are two main types of brain tumour:
- Non-cancerous (benign) brain tumours: these grow slowly and do not spread
throughout the body.
- Cancerous (malignant) brain tumours: these grow faster and can spread to other parts
of the body.
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Brain tumours that start in the brain are known as primary tumours. If they have spread
to the brain from elsewhere, they are called secondary tumours.
All types of brain tumour are a serious health threat, since the brain controls all the
functions of the body. Both benign and cancerous brain tumours can be fatal. Even
when they are not, they can be very disabling. Symptoms can include:
- Headaches
- Epileptic seizures (fits)
- Persistent nausea (feeling sick), vomiting, and drowsiness
- Changes in behaviour or personality, trouble thinking, memory problems
- Weakness, or paralysis that develops on one side of the body
- Problems with speech or vision
It is difficult to diagnose brain tumours, because symptoms can all be mistaken for
those of less serious conditions. It may take some time before their true cause – a brain
tumour – is identified. Yet diagnosing a brain tumour as early as possible is important,
because the bigger a tumour grows, the more difficult it is to treat, and the greater the
potential for the treatment to cause collateral damage.
A range of initiatives has been designed to speed up the diagnosis of brain tumours.
This includes campaigns to increase doctors’ and the public’s awareness of the
symptoms they cause, and professional guidelines to speed up referral for diagnostic
scans or specialist assessment. To find out how effective these initiatives are, we set
out to review the research evidence. We also wanted to investigate the cost of
initiatives.
How we searched for evidence
 
Our team of researchers searched the medical literature for studies that compared the
effectiveness of an initiative designed to speed up the diagnosis of brain tumours
against normal practice or another initiative, and included people of all ages with signs
or symptoms that might suggest a brain tumour.
What we found
 
We found 115 studies that investigated the diagnosis of brain tumours, but none of
them met all of our inclusion criteria, and we excluded them. We found no studies with
information about the cost of initiatives.
What this means
 
Currently, there is no evidence from good quality studies to inform patients, health
professionals, or service planners about how to reduce the time to diagnosis of brain
tumours. Nor is there any information on the cost of these initiatives. This review
highlights the need for research in this area.
How up-to-date is this review?
 
We last searched for evidence in January 2020. This review covered research that was
available up to that date, but did not consider any evidence that may have been
produced since then.
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Background
Description of the condition
Primary brain tumours are a heterogeneous group of tumours arising from the brain
substance and its surrounding structures, and may be high or lower grade. Primary
intracranial brain tumours can be divided into primary intracerebral tumours (e.g.
gliomas, pinealomas, medulloblastomas, etc), or primary extracerebral tumours, arising
from structures outside the brain but within the cranium or skull (i.e. meningiomas,
neuromas, adenomas). Secondary intracranial brain tumours arise from tissues outside
the brain, and spread to the brain and tissues within the skull (secondary intracerebral
metastases). All types of intracranial tumours can form mass lesions and can cause
similar symptoms, e.g. headache, or focal neurological symptoms, e.g. neurological
weakness or numbness, language problems, epileptic seizures, or cognitive or
personality changes, depending on where they are within, or pressing on the brain.
Epidemiological studies show about 50% of all intracranial tumours are primary, and
50% are secondary with incidences of 10 to 16 per 100,000 per year for each
(Barnholtz-Sloan 2004; Counsell 1996; de Robles 2015; Materljan 2004; Nayak 2012;
Ohgaki 2009; Walker 1985). Gliomas account for 2% of all cancers and have an
incidence of about 6 to 8 cases per 100,000 per year (Bell 2019; de Robles
2015; GLOBOCAN 2018; Ohgaki 2009). Incidence varies across regions, with 6 to
7 cases per 100,000 person-years in Europe, to around 3 per 100,000 person-years in
Africa (Bell 2019; de Robles 2015). Estimated new cases of brain and other nervous
system tumours amounted to approximately 24,000 in the USA in 2018 (Siegel 2019). 
In high-income countries, on average, 10% to 15% of all cancers spread to the brain,
giving an incidence of brain metastases of about 16 cases per 100,000 per year in
these settings (Nayak 2012). Although most brain metastases occur as a late
manifestation of cancer, over 10% of people with lung cancer present with brain
metastases as a first symptomatic site (Nieder 2019). 
Clinicians often find it very difficult to make a diagnosis of a brain tumour, as presenting
symptoms, such as headaches, or cognitive and personality symptoms, may be more
commonly attributable to other conditions, such as migraine, anxiety, depression,
stress, or dementia. Most people with primary brain tumours have seen their general
practitioner (GP) before diagnosis, often several times (Lyratzopoulos 2013; Swann
2020; Walter 2019), but more than 50% subsequently present to, or are diagnosed by
emergency services rather than by their GP, or in a clinic setting (Elliss-Brookes 2012).
Brain tumours are recognised as one of the most difficult cancers to diagnose in
general practice, and even expedited pathways to hospital referral or imaging (e.g.
maximum of a two-week wait for suspected cancer) will be useful in only a small
percentage of cases (Hamdan 2013). Subtle, non-alarming symptoms and signs may
predate headaches (Scott 2019); these, such as personality changes, are often first
noticed by a spouse (Salander 1999). Headaches may be the earliest presenting
symptom (Grant 2004), and the delay between symptom onset and diagnosis may
be greatest in people presenting with headaches or cognitive issues (Ozawa 2018).
The poor detection rate based on referral guidelines, and the delays in the pathway to
diagnosis, may ultimately influence management and prognosis. There is a lack of data
on whether cancer referral guidelines, such as the National Institute for Health and
Care Excellence (NICE; Bates 2018; NICE 2006), the Scottish Cancer Referral
Guidelines (SCRG 2019), or the Canadian guidelines have been helpful in selecting
cases more accurately. A 2019 study demonstrated that the positive predictive value of
the NICE symptom-based referral guidelines was very low, at only 2.9% (Zienius 2019).
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In addition, it is also uncertain whether any expedited referral pathways in the UK, such
as the Suspected Cancer Pathway (NICE 2017), or Direct Access Diagnostic Imaging
(NHS 2014), have improved early diagnosis, or whether they are cost-effective
(Simpson 2010).
In general, cancer referral guidelines delineate four different presentations of brain
tumours that require urgent referral upon suspicion:
progressive neurological deficit, e.g. progressive weakness or sensory problem
down one side of the body, speech or language problems, or unsteadiness;
late onset seizure;
headache with cognitive or behavioural symptoms; and
headache with papilloedema (swelling of the optic disc).
According to NICE 2017, an urgent, direct access magnetic resonance imaging (MRI)
scan of the brain (or computed tomography (CT) scan, if MRI is contraindicated) should
be performed within two weeks in adults with progressive neurological deficit.
Headache with papilloedema may be a very late presentation, meaning that the tumour
has reached a substantial size, or is blocking cerebrospinal fluid pathways, and is
suggestive of life-threatening disease. Ideally, clinicians will diagnose people based on
the history of progressive headache, with certain 'red flags' that predict a more serious
cause for the headache (such as a headache that is worse in the morning, on stooping
and straining, and accompanied by vomiting or drowsiness). In people with headache
and papilloedema, which denotes raised intracranial pressure, clinicians are advised to
consider same-day emergency referral, or referral within 48 hours (SCRG 2019).
A cancer referral pathway and service re-design have been recommended, including
supportive interventions to achieve quality and productivity targets, to facilitate
implementation of the NICE Guidelines for Suspected Cancer (Macmillan 2016). Such
interventions will require evaluation to see if they speed up diagnosis without adding an
increased burden on imaging services (Penfold 2017).
Description of the intervention
Interventions to reduce the time to diagnosis of brain tumours include expedited
pathways to diagnose brain tumours based on a person's presenting symptoms and
signs. In the UK, in the past decade, there have been several local and regional service
re-design and expedited pathway initiatives, aimed at early identification of people who
have symptoms and signs that suggest brain tumour should be one of the differential
diagnoses. Neurological services have largely been re-designed to expedite pathways
associated with focal (stroke-like) neurological presentations, late onset epilepsy ('first
fit' clinics), and specialist neurology clinics to manage urgent referrals ('two-week wait'
clinics), for those with suspicion of cancer (NHS 2013). Neuroradiology services have
also been re-designed to accept direct access cerebral imaging (MRI or CT) referrals
from primary care, whereby a person can be referred for diagnostic imaging without a
specialist's referral (NHS 2014). Cases referred for direct access imaging are more
likely to be people who present with headache, suspicious of cancer and recent
cognitive problems, rather than those who present with focal neurological symptoms
and signs or seizures that necessitate urgent clinical evaluation and management of the
structural cause.
A study of brain tumour cases from a UK national audit of cancer diagnosis in primary
care showed that the most common presentations were progressive focal (stroke-like)
neurology (33%), 'fits, faints, or falls' (21%), and headache (21%) (Ozawa 2018). Other
studies have used routinely collected English primary care data to estimate the
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predictive value of common presenting symptoms (Dommett 2013; Hamilton 2007;
Kernick 2008). A systematic review of these sorts of studies found that common
symptoms, apart from new-onset epilepsy, had low positive predictive values (PPVs) for
brain tumours (Schmidt-Hansen 2015); in this review, headache was found to have a
PPV of less than 1%. In a recent large case-control study, using five-year data from the
UK clinical practice research database, headache, as a symptom on its own, was also
reported to be a weak predictor of adult brain tumours (PPV = 0.1%); however, its
predictive value was enhanced when combined with other symptoms (Ozawa 2019).
For example, headache combined with cognitive symptoms gave a PPV of 7.2%, and
combined with weakness gave a PPV of 4.4%. Late-onset seizure had the highest PPV
of all individual symptoms in this study, of 1.6%.
Thus, strategies to reduce the time to diagnosis may include the following:
expedited pathways to diagnose those with stroke-like presentation;
expedited pathways to diagnose those with late-onset seizures;
expedited pathways to diagnose those with suspicion of cancer within a target
referral time;
expedited imaging pathways to diagnosis those with headache, suspicious of
cancer;
expedited imaging pathways to diagnose those with recent cognitive problems;
interventions to reduce waiting times for brain imaging pathways (CT or MRI),
such as direct access imaging; and
national awareness and early diagnosis initiatives.
How the intervention might work
These interventions might work to:
increase population awareness of the presenting features of brain tumours
through publicity campaigns, which may lead to people presenting to their GPs
earlier (See Figure 1 – Patient interval);
increase awareness of the presenting features of brain tumours (GP education),
and of new available pathways to refer people (e.g. urgent neurology clinics or
fast access, direct cerebral imaging) might result in an earlier referral for scanning
(See Figure 1 – Doctor interval) or hospital opinion (see Figure 1 – Primary care
interval);
shorten waiting times for urgent referrals (e.g. electronic system referral for
appointments, urgent cerebrovascular clinics, first fit clinics, urgent neurology
clinics) to reduce the delays in hospital once the referral has been received (see
Figure 1 – Secondary care interval to diagnosis);
reduce time from first clinical appearance to diagnosis (e.g. by increasing number
of scanners, increasing hours of scanning within the day, increasing open access
imaging for primary care or protocol-based referral for urgent imaging, using
private or insurance-based system for direct access imaging; See Figure 1 –
Diagnostic interval).
If these interventions reduce time to diagnosis, it might make it less likely that people
experience clinical deterioration on waiting lists, necessitating self-referral or primary
care referral to emergency units for evaluation and imaging. On a national level,
changes associated with interventions to reduce time to diagnosis might be evident
within the longitudinal, routinely-collected data gathered by national cancer bodies
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through, for example, Routes to Diagnosis (Elliss-Brookes 2012), National Cancer
Waiting Times Monitoring Datasets NHS 2019), and diagnostic test access monitoring
(NCRAS 2012). However, the effectiveness of individual interventions might also be
measured through comparative evaluation of local or national waiting times, and the
proportion of people with brain tumours diagnosed via imaging, within target time
intervals.
Why it is important to do this review
To our knowledge, no systematic reviews have been conducted on this topic to date.
The James Lind Alliance (JLA) brings together participants, carers, and clinicians to
agree which clinical areas matter most and deserve priority attention (JLA 2015). In
2015, the JLA Neuro-oncology Priority Setting Partnership identified 10 clinical areas in
brain and spinal cord tumours on which the research community should focus. Early
diagnosis was one of the top 10 priorities. The specific research question was 'Does
earlier diagnosis improve outcomes, compared to standard diagnosis times, in people
with a brain or spinal cord tumour?' This is important because brain tumours have a
disproportionate mortality and morbidity compared to their incidence. For example, in
the USA, it has been estimated that central nervous system tumours (1.4% of all
cancers) causes 2.9% of cancer deaths (Siegel 2019). This effect is greatest in younger
people; brain tumours kill more people under the age of 49 in the UK than any other
form of cancer (CRUK 2019).
Early diagnosis has also been highlighted by Cancer Research UK as a key target for
brain tumour research (CRUK 2016). Interventions that shorten the time to diagnosis of
suspected cases may impact the severity of symptoms at diagnosis, allowing different
surgical possibilities (e.g. resection of tumour versus biopsy only), and influencing the
choice of further oncology treatment. This may result in better tolerance and response
to radiation therapy and chemotherapy, and reduce the burden of a remaining large
intracranial tumour. Therefore, earlier diagnosis might ultimately improve the survival of
people with brain tumours. Reducing delays along the diagnostic pathway can also
reduce service users' distrust in primary care and dissatisfaction with the healthcare
system.
There is also a significant resource implication associated with managing brain
tumours. The costs of managing brain tumours in Europe has been estimated to be 
€PPP 21,590 per person (PPP = purchasing power parity of 2010; DiLuca 2014). It has
also been estimated that central nervous system cancers resulted in the loss
of 721,787 DALYs (Disability Adjusted Life Years – a unit that combines the
morbidity and mortality associated with a disease) in Western Europe (GBD 2019). This
illustrates that brain tumours have a significant impact on healthcare resources and
population health. Understanding strategies that have the potential to allow early
diagnosis and possibly result in better outcomes with less aggressive treatment is
crucial when considering future policy. 
Objectives
To systematically evaluate evidence on the effectiveness of interventions that may
influence: symptomatic participants to present early (shortening the patient interval),
thresholds for primary care referral (shortening the primary care interval), and time to
imaging diagnosis (shortening the secondary care interval and diagnostic interval).
To produce a brief economic commentary, summarising the economic evaluations
relevant to these interventions.
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Methods
Criteria for considering studies for this review
Types of studies
Randomised and non-randomised comparative studies, including cluster-RCTs and
controlled before-after studies (CBAs) that control for baseline differences. We
excluded cross-over designs, case-control studies, and studies without a comparison
group.
Types of participants
People of any age with a presentation that might suggest a primary brain tumour,
specifically focal neurological deficit, headache suspicious of cancer, recent cognitive
problems, and late onset seizures. It is accepted that only a small proportion of people
would ultimately have a brain tumour, although it would be within the differential
diagnosis. We did not plan to exclude participants with a past history of systemic
cancer, but had planned to manage these data as a separate subgroup if we found any.
Types of interventions
Any active intervention that may influence the diagnostic pathway, e.g. clinical
guidelines, direct access imaging, public health campaigns, educational and other
interventions that might lead to early identification of primary brain tumours.
Types of outcome measures
Primary and secondary outcome measures are as follows.
Primary outcomes
Time from first symptom to diagnosis (brain imaging, or as defined by study
authors)
Time from first presentation to diagnosis (brain imaging, or as defined by study
authors)
Secondary outcomes
Proportion of people identified with brain tumours (any type) of those referred with
suspicious symptoms
Performance status at imaging diagnosis (e.g. Karnofsky Performance Status,
WHO Performance Status, Barthel Disability Index, or Modified Rankin Handicap
Scale, if available, with thresholds as reported by study investigators)
Health-related quality of life (QoL) at diagnosis, or imaging, or other time points up
to diagnosis (e.g. the European Organisation for Research and Treatment of
Cancer (EORTC) QLQ-C30 or EQ5D-5L)
Proportion of people with possible brain tumour experiencing delayed diagnosis or
brain imaging (e.g. more than two weeks after referral)
Proportion of people with brain tumours diagnosed after emergency
presentation (a surrogate for late diagnosis) compared with those diagnosed
through primary care referral pathways 
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We also planned to present any evidence regarding cost of care, as a brief economic
commentary.
Search methods for identification of studies
Electronic searches
We searched the following databases from 2000 (This is when the UK National Cancer
Plan was introduced by the UK's Department of Health with Referral guidelines for
suspected cancer, which has been updated and replaced by NICE 2017) to 13 January
2020:
Cochrane Central Register of Controlled Trials (CENTRAL; 2020, Issue 1), in the
Cochrane Library;
MEDLINE via Ovid (2000 to December week 4 2019);
Embase via Ovid (2000 to 2020 week 1).
For economic evidence, we searched the EED database from the end of December
2014 (when the last records were added to that database) to January 2000, and
MEDLINE and Embase from 1 January 2015 to January 2020, as NHS EED already
included comprehensive searches of these databases prior to 2015. We also
considered relevant grey literature, such as health technology assessments, reports,
and working papers, for inclusion.
Please refer to Appendix 1 for CENTRAL, MEDLINE, and Embase search strategies.
We did not apply language restrictions to any of the searches.
Searching other resources
We searched Clinicaltrials.gov on 1 May 2020. We also handsearched conference
proceedings from 2014 to 2018 (five years) of conferences of the British Neuro-
oncology Society, the Society for Neuro-oncology, the European Association of Neuro-
oncology, and the World Federation of Neuro-oncology Societies to identify other
relevant ongoing or unpublished studies.
Data collection and analysis
We used Cochrane methodology for data collection and analysis as follows.
Selection of studies
After removing duplicates, the Information Specialist at the Cochrane Gynaecological,
Neuro-oncology and Orphan Cancer Group (GNOC) downloaded all titles and abstracts
retrieved by electronic searching to Covidence to facilitate study selection. Two review
authors (TL, ET) independently screened these records and obtained copies of the full
texts of potentially eligible references. At least two review authors (TL, ET, DH, TD)
independently assessed each full text for eligibility. Disagreements were resolved by
discussion, or by consultation with another reviewer (RG), or the wider group of review
authors, if necessary. We have documented reasons for exclusion in the Characteristics
of excluded studies tables of the review.
In this version of the review, we did not identify any studies eligible for inclusion. In
future versions, if any studies meet the inclusion criteria, we will use the following
methods:
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Data extraction and management
Three review authors (TL, ET, TD) will independently extract the following data from any
eligible studies to a piloted data extraction form. We will resolve discrepancies through




Dates of participant accrual
Trial registration number or identification
Funding source
Declarations of interest
Participant inclusion and exclusion criteria
Study design and methodology
Study population and baseline characteristics












Primary outcome(s) of the study
Review outcomes
For dichotomous outcomes, we will extract the number of participants in
each treatment arm who experienced the outcome of interest, and the
number of participants assessed
For continuous outcomes, we will extract the value and standard deviation of
the outcome of interest, and the number of participants assessed at the
relevant time point in each group. We will also extract change-from-baseline
score data, where reported, and note the type of scale used
We will extract adjusted statistics, where reported
Where possible, all data extracted will be those relevant to an intention-to-
treat analysis, in which participants are analysed in the groups to which they
were assigned
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We will resolve differences between review authors by discussion, or by
appeal to the other review authors, when necessary
Risk of study bias (see below)
Assessment of risk of bias in included studies
For randomised trials, we will assess the risk of bias using Cochrane's tool and the
criteria specified in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). This includes assessment of:
random sequence generation;
allocation concealment;
blinding of participants and healthcare providers;
blinding of outcome assessors;
incomplete outcome data (more than 20% missing data considered high risk);
selective reporting of outcomes;
other possible sources of bias, e.g. insufficient number of participants, baseline
differences in group characteristics.
For non-randomised studies (non-randomised trials and controlled before-after studies),
we will use the ROBINS-I tool for assessing risk of bias (Sterne 2016). This includes
assessment of:
bias due to confounding (e.g. baseline differences in prognostic factors, or post-
baseline prognostic factor differences, or switching interventions);
bias due to participant selection (both intervention and comparison groups should
comprise the same representative group);
bias in classification of interventions (e.g. differential misclassification
of intervention status that is related to the outcome or the risk of the outcome);
bias due to deviations from intended interventions;
bias due to missing data (e.g. differential loss to follow-up that is affected by
prognostic factors);
bias due to outcome measures (e.g. outcome assessors are aware of intervention
status, different methods are used to assess the outcome, or measurement errors
are related to intervention status or effects);
bias in selection of the reported result.
Two review authors (TL, ET or TD) will independently assess risk of bias, and resolve
differences by discussion or by appeal to another review author (RG). We will
summarise judgements in 'Risk of bias' tables, along with the characteristics of any
included studies. We will interpret results in light of the 'Risk of bias' assessment. For
more details about the assessment of risk of bias, see Appendix 2.
Measures of treatment effect
For dichotomous outcomes, we will calculate the effect size as a risk ratio (RR)
with its 95% confidence interval (CI).
For continuous outcomes (e.g. QoL scores), in which the same measurement
scales were used, we will pool data as a mean difference (MD) with its 95% CI. If
studies used different time points and measurement scales, and we consider it
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clinically meaningful to do so, we will pool data using the standardised mean
difference (SMD).
For time-to-event data, we will calculate the effect size as a hazard ratio (HR) with
its 95% CI.
Unit of analysis issues
At least two review authors will independently review unit-of-analysis issues (TL, TD),
as described in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011), for each included study. These include reports where there are multiple
observations for the same outcome, e.g. repeated measurements with different scales,
or outcomes measured at different time points. When time points differ across studies,
or there are multiple observations for the same outcome, we will synthesise the findings
narratively.
We will analyse cluster-randomised trials alongside individually-randomised trials, and
will adjust their sample sizes using the methods described in the Cochrane Handbook
for Systematic Reviews of Interventions using an estimate of the intra-cluster correlation
co-efficient (ICC) derived from the trial (if possible), from a similar trial, or from a study
of a similar population, if the authors had not taken clustering into account. We will
report the source of the ICC and conduct sensitivity analyses to investigate the effect of
variation in the ICC. We consider it reasonable to combine the results from both cluster-
randomised and individually-randomised study designs if there is little heterogeneity
between the study designs, and we consider the interaction between the effect of
intervention and the choice of randomisation unit to be unlikely. We will acknowledge
heterogeneity in the randomisation unit, and perform subgroup analysis to investigate
the effects of the randomisation unit. We will resolve differences by discussion with a
third review author (RG).
Dealing with missing data
For included studies, we will note the levels of attrition, but will not impute missing data.
In the event of missing data, we will write to study authors to request the data, and
describe in the 'Characteristics of included studies' table how we obtained any missing
data. We will explore the impact of including studies with high level of missing data in
the overall assessment of treatment effect by using sensitivity analysis.
Assessment of heterogeneity
We will assess statistical heterogeneity between studies by visual inspection of forest
plots (Higgins 2003), and by using a formal statistical test of the significance of the
heterogeneity, assessed using the T², I², and Chi² statistics (Deeks 2001). We will
regard heterogeneity as substantial if an I² is greater than 60%, and either T² is greater
than zero, or there is a low P value (< 0.10) in the Chi² test for heterogeneity. Where
there is evidence of substantial heterogeneity (I² > 60%), we will investigate and report
the possible reasons for it, e.g. clinical heterogeneity, high risk of bias studies, etc.
Should we use a different approach to synthesis, which does not support production of
a forest plot with effect sizes, it may still be useful to report on heterogeneity in the
standardised effect measure used, e.g. effect direction, which is akin to an informal
sensitivity analysis, the results of which are speculative, but may be useful for readers. 
Assessment of reporting biases
Where there are 10 or more studies in a meta-analysis, we will investigate reporting
biases, such as publication bias, through visual inspection of funnel plots. If asymmetry
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is suggested by visual assessment, we will perform exploratory analyses to investigate
it.
Data synthesis
We will pool dichotomous data as risk ratios (RRs), and continuous data as mean
differences (MDs) or standardised mean differences (SMDs) if different scales have
been used. We will use the random-effects model with inverse variance weighting in
Review Manager 2014, because we expect clinical heterogeneity among included
studies. We will treat the random-effects summary as the average range of possible
intervention effects, and we will discuss the clinical implications of intervention
effects differing between trials. If any trials contributing to a meta-analysis have multiple
intervention groups, we will divide the 'shared' comparison group into the number of
treatment groups and comparisons between each treatment group, and treat the split
comparison group as independent comparisons.
If different studies report either dichotomous or continuous data for the same outcome,
we will attempt to convert continuous data to dichotomous data to facilitate meta-
analysis.
Assuming we find at least two included studies that are sufficiently similar for the
findings to be clinically meaningful, we will perform a meta-analysis of the results. If it is
not clinically meaningful to pool data, we will attempt a narrative synthesis of the
evidence.
We will synthesise data from non-randomised studies separately from randomised
trials. As different non-randomised studies may report results in different ways, when
found, we may tabulate this sort of evidence and synthesise it narratively.
In any evidence synthesis (meta-analysis and narrative synthesis), we will subgroup
interventions and strategies according to how they might work (see How the
intervention might work). If data are very sparse, we may report raw data from individual
studies.
Brief economic commentary
We will develop a brief economic commentary, based on current methods guidelines, to
summarise the availability and principal findings of trial-based and model-based full
economic evaluations (cost-effectiveness analyses, cost-utility analyses, cost-benefit
analyses) that evaluate interventions that aim to reduce the time to diagnosis of brain
tumours (Shemilt 2019). This commentary will focus on the extent to which principal
findings of eligible economic evaluations indicate that an intervention might be judged
favourably (or unfavourably) from an economic perspective, when implemented in
different settings.
Subgroup analysis and investigation of heterogeneity
If it is meaningful to do so, we will synthesise data from different interventions together
in the first instance. If we identify substantial heterogeneity, we will use subgroup and
sensitivity analyses to investigate it. Where there are sufficient data, we anticipate the
following subgroup analysis.
Type of intervention: e.g. clinical guidelines, direct access imaging, public health
campaigns, educational, and other
Type of referral: referral for suspected brain tumour, or referral for other suspected
conditions in which the differential diagnosis includes brain tumour, e.g. epilepsy,
stroke, headache
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Age: children younger than 16 years old, young adults (16 to 40 years old), and
adults older than 40 years
Setting: high-income country and low- or middle-income country settings
We will use formal tests for subgroup differences.
Sensitivity analysis
We plan to perform sensitivity analyses (i) to investigate instances of substantial
heterogeneity identified in meta-analyses of the primary outcomes, and (ii) to
investigate how study quality affects the estimate of effect after excluding studies at
high risk of bias.
Summary of findings and assessment of the certainty of the evidence
Based on the methods described in Chapter 11 of the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011), we will prepare a 'Summary of
findings' table to present the results of the following outcomes:
time from first symptom to diagnosis;
time from first presentation to diagnosis;
proportion of people identified with brain tumours (any type) of those referred with
suspicious symptoms.
We will use the GRADE system to rank the certainty of the evidence, with two review
authors independently grading the evidence, and resolving differences by discussion, or
by involving a third review author (Schünemann 2011). Where the evidence is based on
single studies, or where there is no evidence on a specific outcome, we will include the
outcome in the 'Summary of findings' table, and grade or explain accordingly. We will
provide a rationale for each judgement in the table footnotes. In the absence of a single
estimate of effect (when meta-analysis was not possible), we will rate the certainty of
the narrative evidence using the GRADE approach (Murad 2017). We will interpret the
results of the graded evidence based on Cochrane Effective Practice and Organisation
of Care guidance (EPOC 2017).
Results
Description of studies
We did not identify any studies for inclusion in this review.
Results of the search
Intervention study searches
Electronic searches conducted from January 2000 to 8 August 2019 and 9 January
2020, identified a total of 3032 records after de-duplication. We identified nine additional
records by searching conference proceedings, and three through study reference lists
and related articles searches. Out of the total of 3041 records, we retrieved the full text
of 115. We excluded all potentially eligible studies (see Figure 2).
Economic studies searches
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We conducted searches for economic studies on the same dates as above. The August
2019 search identified 114 records, and the January 2020 search identified 12 records;




We excluded 115 studies or reports mainly for study design reasons, although most
studies had more than one reason for exclusion, e.g. they may also have assessed an
ineligible intervention or ineligible outcomes. Ineligible study designs included:
studies without an intervention and/or control group, e.g. audits (Abernethy 2008;
Ahmad 2009; Baughan 2011; Bergqvist 2017; Braun 2006; Chiesa 2019;
Chrastina 2011; Daverio 2016; Davis 2008; Dommett 2019; Gocan 2016; Grant
2017; Griffiths 2005; Gray 2018; Grooss 2016; Handschu 2015; Harris 2000;
Hatzitolios 2008; Knox 2012; Lange 2011; Lee 2018; Mohammad 2016; Munoz-
Ceron 2019; Pengiran 2003; Simpson 2010; Tatencloux 2017; Umotong 2017;
Webb 2015; Weddell 2017; Williams 2007; Zienius 2019)
reviews (Abend 2010; Aghi 2015; Albert 2016; Al-Okaili 2006; Altindag 2017;
Bartleson 2006; Brat 2008; Brouwers 2009; Cahill 2015; Carter 2007; Faehndrich
2011; Ferro 2017; Fouke 2015; Fowler 2004; Friedman 2011; Furtwangler 2014;
Gaillard 2011; Giguere 2012; Kahn 2014; Langen 2008; Langen 2011; Langen
2017; Langen 2018; Long 2017; Wilne 2007)
uncontrolled before-after studies (Dutto 2009; Guilfoyle 2011; Haneef 2010;
Laursen 2012; Laursen 2012a; Nahab 2012; Rittman 2012; Shack 2016;
Shanmugavadivel 2016; Shanmugavadivel 2020; Walker 2015; Walker 2016)
retrospective case-control studies (Ahrensberg 2016; Kernick 2009)
diagnostic test accuracy studies (Asimos 2014; Titlic 2008)
clinical practice guidelines, recommendations, or consensus reports (Barisic 2012;
Bhat 2011; ESMO 2007; Frappaz 2003; Gago-Veiga 2017; Haswali 2015; Jiang
2016; Larner 2006; Mirsky 2017; Richards 2009; Stupp 2009; Weller 2014; Weller
2017; Wilne 2010)Bhat 2011
qualitative studies (Llewellyn 2018; Molassiotis 2010; Vedelo 2018)
discussion papers (Chenevert 2006; Cianfoni 2007; Cote 2017; Cross 2006; Gaini
2004a; Galiano Fragua 2011; Harada 2007; Kabbouche 2010; Langdon 2017;
Leal 2019; Le Bas 2005; McCrea 2013; Medina 2002; Penfold 2017; Pitfield 2012;
Scharl 2017)
other types of papers (Bachli 2018; Cowan 1999; Davies 1997; Halperin 1996;
Moller-Hartmann 2002; Thust 2018)
See Characteristics of excluded studies. Five of these studies evaluated potentially
relevant interventions (Dutto 2009; Laursen 2012; Pengiran 2003; Walker 2016; Webb
2015). Although we excluded these studies on methodological grounds because they
lacked control groups, for completeness, and to provide pointers for future research, we
describe their findings below.
The HeadSmart study evaluated a UK-wide public and professional awareness
campaign to raise awareness of brain tumour symptoms, and to promote appropriate
assessment, and timely referral and diagnosis of children and adolescents with relevant
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symptoms (Walker 2016). Different symptom checklists were prepared depending on
the child’s age at symptom onset (under 5 years, 5 to 11 years, 12 to 18 years).
Checklists and campaign materials were designed for easy implementation (one
symptom for medical assessment, and two or more for urgent referral to a specialist
centre for further investigations). Campaign materials were made available to health
professionals (general practitioners (GPs), paediatricians, and professional trainers)
and to the public, through mass and social media campaigns, and via cancer charities.
Outcomes included time from symptom onset to first presentation (patient interval); time
from presentation to diagnosis (diagnostic interval); and time to treatment. Public and
professional awareness were also monitored.
Using records of children referred to 18 participating centres, a series of observations
were carried out in the six months before and two years after the launch of the
intervention (monthly observations were recorded during the pre-launch period
(January to June 2011), and in the months following implementation of the campaign
(July 2011 to May 2013). Results were presented for 710 children and adolescents with
pre-launch (January to May 2011) observations for 165, and post-launch (June 2011 to
May 2013) observations for 545 participants. The median time from symptom onset to
diagnoses was reported to have been reduced from 9.1 weeks in the pre-launch period
(January to June 2011) to 6.7 weeks in the second year of the campaign (P = 0.197).
Although the distribution was skewed, the mean time to diagnosis over the same two
periods, reduced from 25.2 weeks to 21.3 weeks. The interval between the first
professional contact to central nervous system imaging was reported to be reduced
from a median of 3.3 weeks to a median of 1.4 weeks during the second year of the
campaign (P = 0.009).
Overall, it is not easy to interpret the data from this study. The results described in the
text were very limited, while the graphs displaying monthly observations suggested
considerable month by month variation in outcomes. There were no clear comparisons
in the text between the before and after periods for most outcomes; rather, authors
reported medians from the pre-launch period and the second year post-launch. There
was also a lack of information on participant characteristics before and after the launch
of the campaign, so it was not clear if there were differences between these groups.
The discussion in the evaluation report points out that the net effect of the campaign
was difficult to separate from the effects of the introduction of a clinical guideline, other
changes in health services, and MRI availability over the study period. In a related
abstract, the study authors stated that between 2006 and 2011 (pre-HeadSmart),
median time to diagnosis had already fallen from a median of 13.4 to 6.3 weeks (Walker
2015). So the added effect of HeadSmart was not easy to disentangle. We also found it
difficult to interpret the effects of the campaign in different settings. In the discussion
section of the HeadSmart evaluation report, they stated that children attending the
emergency department had the most rapid referral for diagnostic imaging; it was not
clear whether GPs (who were a major focus of campaign materials) referred children
any more rapidly before or after the campaign.
In another before-after study conducted in Italy, Dutto 2009 examined the
implementation of a headache diagnosis protocol (a series of decision charts) in an
urban hospital emergency department. Participants were adults presenting with non-
traumatic, non-fever headaches over the six-month study period from April 2006 to
September 2006. These participants were compared with retrospective controls (using
case notes for people attending between April 2005 and September 2005). The aim of
the intervention was to improve the diagnosis of headaches associated with serious
conditions (e.g. stroke or neoplasms). Outcomes included resource use (CT scans,
neurological consultations, and hospital admission), early diagnosis, and death. Two
independent observers examined the case records of people who met the eligibility
criteria in the six months before (N = 312) and after (N = 374) the introduction of the
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intervention. Altogether, they identified a total of 30 serious, secondary headaches. The
trial authors reported that during the 'after' period, during which the protocol had been
'strictly applied (66%), there was an 11.3% reduction in neurological consultations.
However overall, there was little difference in outcomes before and after the diagnosis
protocol was introduced, with only a small number of neoplasms identified during both
periods (two before and five after the intervention). The lack of a control group and the
low number of neoplasms identified in this before-after study meant that results were
difficult to interpret.
Laursen 2012 examined the implementation of the Danish Integrated Cancer Pathway,
which aimed to improve diagnosis and clinical management for 34 types of cancer. The
brain tumour pathway set out clear criteria for the referral of people suspected of having
brain malignancies. Evaluation was carried out over two years (with data for eight three-
month periods) after the introduction of the pathway. We excluded the study as it had
no control group or data prior to the intervention. Outcomes included the number of
appropriate referrals, and time from hospital admission to diagnostic tests and final
diagnosis. The study authors reported that the clear criteria for referral resulted in a
reduction of approximately 25% in participants enrolled in the brain tumour pathway
over the study period. Data for 241 participants showed that the mean time from
hospital admission to final diagnoses was reduced from approximately three days
during the first quarter following the introduction of the pathway, to approximately two
days by the end of the two-year study period.
We excluded two other UK studies because they lacked control groups. Pengiran 2003
evaluated the impact of an urgent (two-week) referral guideline for suspected brain
tumours using retrospective audit, without a control group. The guideline set out
specific criteria for GPs to use to refer for specialist care. The aim was to reduce
inappropriate referral and reduce delay for those with symptoms of serious neurological
conditions. Prior to the implementation of the guideline, there was no fixed system to
refer people with cancer, although people deemed to be urgent in the GP referrals,
were seen within one week. In the three months before the introduction of the guideline,
neurological clinic records indicated that of 12 people urgently referred, none had
cancer. The subsequent case audit over a nine-month period, from July 2000 to April
2001 (after guideline implementation) included 43 people. Four people included in the
audit had malignancies; two primary brain tumours and two brain metastases, and all
four had met the referral criteria. However, 30% of urgent referrals did not adhere to
guidelines. The authors concluded that specific criteria for referral may reduce
inappropriate resource use, and thereby, improve timely access for with serious
disease.
Webb 2015 evaluated the same urgent referral pathway as Pengiran 2003, using a
retrospective case review of referrals between January 2009 and September 2013. The
study sought to determine the number of people who were appropriately referred, and
the effectiveness of the pathway on the numbers of people offered specialist
appointments within 14 days, and on the time to scan report. All 105 people referred
received an offer of a specialist appointment within 14 days; the median time to scan
report after referral was 18 days (interquartile range (IQR) 9 to 23 days). Ten brain
tumours were identified from the 105 people referred. The trial authors concluded that
there were frequent, inappropriate, low-risk referrals. Although the study suggested that
people on the urgent referral pathway were generally seen within the two-week target
period, it was not clear how this may have differed from previous care, as no data on
the period before the introduction of the pathway were presented.
Risk of bias in included studies
Not applicable.





Summary of main results
In this version of the review, we did not identify any studies evaluating intervention
effectiveness that met the review inclusion criteria.
Brief Economic Commentary 
We did not identify any economic studies that analysed the use of any strategies to
reduce time-to-diagnosis for brain tumours. The apparent shortage of relevant
economic evaluations indicates that there is a paucity of economic evidence on the
efficiency of potential strategies that aim to reduce the interval for diagnosis of brain
tumours.
Overall completeness and applicability of evidence
This review, for which no studies met the inclusion criteria, highlights that evidence on
how to reduce the time to diagnosis of brain tumours is an important knowledge gap.
Quality of the evidence
In this version of the review, we were unable to include any of the studies identified by
our search strategy. The main reason for exclusion of potentially eligible studies was
study design. We did not identify any randomised controlled trials or controlled before-
after studies examining relevant interventions. As we describe above, we did identify a
small number of studies focusing on eligible participants and interventions, but these
studies were all at high risk of bias as they did not include control groups. Under these
circumstances, we were not able to ascertain whether outcomes were due to
interventions or were influenced by other possible confounding factors. For example, in
the Headsmart study, we were unable to conclude, with any confidence, whether the
positive effects identified were attributable, even in part, to the effects of the awareness
campaign, or were related to other background factors, such as changes in health
policy, or diagnostic technologies, or both, over the study period (Walker 2016). At the
same time, such studies do offer useful information on potentially promising
interventions, and clarification of the participant subgroups most likely to benefit from
more timely diagnosis; this may help to target interventions and inform the design of
future evaluations.
Potential biases in the review process
We are mindful that the review process itself may introduce bias. We took steps to
minimise the potential for such bias by ensuring that at least two members of the review
team, working independently, screened titles identified by the search strategy. A
minimum of two reviewers independently assessed the full text of reports for potentially
eligible studies. Where we had any doubt, or where there was discrepancy between
review authors on whether or not a study should be included, we consulted the wider
review team. In future versions of the review, if we identify any studies for inclusion, we
will apply the strategies set out in the methods section, in a bid to reduce bias.
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Agreements and disagreements with other studies or
reviews
We excluded a number of studies evaluating potentially relevant interventions on
methodological grounds. These included before-after studies and retrospective studies
without control groups. Although we were unable to include these studies in our results,
they may offer some useful insights into possible settings, participant groups, and
interventions for assessment in future controlled trials.
Authors' conclusions
Implications for practice
There is no evidence from good quality studies to inform service users, health professionals, or
service planners on to how to reduce the time to diagnosis of brain tumours, despite the
prioritisation of research on early diagnosis by the James Lind Alliance in 2015.
Implications for research
This review highlights the urgent need for research in this area. Research studies should
include concurrent control groups, so that effects of the interventions can be clearly
ascertained when compared with no or other interventions. Due to the relatively low incidence
of brain tumours, investigators should consider multi-centre collaboration to ensure that studies
are adequately powered to detect a difference. The following types of studies should be
considered:
To reduce the patient interval: studies comparing the effects of a regional campaign in
one area with another area that is not exposed to the intervention;
To reduce the doctor or primary care interval: studies comparing new pathways (e.g. fast
access clinic) to refer people in one region with another region without the intervention
(control); or 'point of care' randomisation to a given pathway, such as (a) open access
MRI, or (b) neurology referral, with the end point of time to scanning diagnosis;
To reduce the secondary care interval: randomisation of referral centres to a
new protocol-based referral for expedited imaging versus the usual pathway;
or randomisation to central imaging centres compared with a standard pathway;
To reduce the diagnostic interval: studies comparing the impact of new service
developments (e.g. new scanners, more scanner time, direct access imaging) in regions
with regions with no change in services. 
The role of a serum-based blood test as a triage tool is currently undergoing evaluation in a
clinical trial (Gray 2018). This intervention is aimed at reducing the primary care interval by
identifying those people with suspicious symptoms most at risk of a brain tumour and
prioritising them for further investigation.
Studies that determine whether early diagnosis impacts survival would be of interest.
What's new
Date Event Description
4 September 2020 Amended Author order amended.
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Characteristics of excluded studies [ordered by study
ID]
Study Reason for exclusion
Abend 2010
This is a review looking at the assessment and management of secondary headaches
in children and adolescents. There was no intervention, and the study was excluded
as it did not meet study design criteria.
Abernethy 2008
This letter describes two post-intervention audits following the introduction of a 2-
week referral guideline for people suspected of having cancer, and referred to an
outpatient neurology clinic. There was no control group, and the study is not eligible
for inclusion in the review as it did not meet study design criteria.
Aghi 2015
This is a review looking at patients with newly diagnosed, WHO grade 2
oligodendroglioma, astrocytoma, or oligo-astrocytoma, or imaging suggestive of
these. The study focused on the accuracy of diagnosis; there was no intervention.
The study is not eligible for inclusion in the review as it did not meet study design
criteria.
Ahmad 2009
This is a retrospective study examining the introduction of a rapid access
neurovascular clinic (TIA). There was no control group, and the study is not eligible
for inclusion in the review as it did not meet study design criteria.
Ahrensberg 2016
This is a retrospective case control study exploring the use of primary care pre-cancer
diagnosis services in adolescents and young adults. There was no intervention or
control group, and the study is not eligible for inclusion in the review as it did not meet
study design criteria.
Al-Okaili 2006 This is a descriptive review of imaging techniques for brain tumours in adults. It is noteligible for inclusion in the review as it did not meet study design criteria.
Albert 2016
This is a review of imaging techniques, providing recommendations for PET imaging
in gliomas. The focus was on tumour differentiation. It is not eligible for inclusion in
the review as it did not meet study design criteria.
Altindag 2017
This is a review of management and treatment of epilepsy in children. There was no
intervention. There was no control group, and it is not eligible for inclusion in the
review as it did not meet study design criteria.
Asimos 2014
This is a retrospective study evaluating the sensitivity and specificity of two out-of-
hospital stroke diagnosis screening tools. It is not eligible for inclusion in the review as
it did not meet study design criteria.
Bachli 2018 This is a laboratory study analysing 13 paediatric CNS tumour samples. It is noteligible for inclusion in the review as it did not meet study design criteria.
Barisic 2012
This is a description of a Croatian guideline outlining the diagnosis and treatment of
headaches in children. There was no intervention or control group, and it is not
eligible for inclusion in the review as it did not meet study design criteria. The original
paper was in Croatian, and we made the assessment of eligibility based on an
abstract in English.
Bartleson 2006
This is a review discussing the management of people with headache. There was no
intervention. The study had no control group, and it is not eligible for inclusion in the
review as it did not meet study design criteria.
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Study Reason for exclusion
Baughan 2011
This is a retrospective case review of urgent, suspected cancer referrals over a 6-
month period. There was no control group, and it is not eligible for inclusion in the
review as it did not meet study design criteria.
Bergqvist 2017
This is a retrospective register-based study looking at the most common intracranial
tumour types. There was no intervention, and the study had no control group. It is not
eligible for inclusion in the review as it did not meet study design criteria.
Bhat 2011
This is a consensus report prepared after a national consultation on paediatric brain
tumours in India in 2008. It was not eligible for inclusion in the review as it did not
meet study design criteria.
Brat 2008
This is a review assessing the role of neuropathology in the diagnosis of malignant
glioma. It is not eligible for inclusion in the review as it did not meet study design
criteria.
Braun 2006
This is a retrospective study looking at the process of diagnosis in children with
stroke. There was no intervention and the study had no control group. It is not eligible
for inclusion in the review as it did not meet study design criteria.
Brouwers 2009
This is a systematic review exploring the optimal organisation for the delivery of
diagnostic cancer services. It is not eligible for inclusion in the review as it did not
meet study design criteria.
Cahill 2015
This is a systematic review and guideline looking at the role of neuropathology in the
management of people with diffuse low grade glioma. It is not eligible for inclusion in
the review as it did not meet study design criteria.
Carter 2007
This is a review exploring the use of CT and MRI imaging in the characterisation of
intracranial mass lesions. It is not eligible for inclusion in the review as it did not meet
study design criteria.
Chenevert 2006 This is a descriptive article discussing diffusion imaging. It is not eligible for inclusionin the review as it did not meet study design criteria.
Chiesa 2019
This is a conference abstract discussing the OMNYBuS project, which aimed to
investigate the impact of multidisciplinary meetings in brain tumour management.
There was no control group, and it is not eligible for inclusion in the review as it did
not meet study design criteria.
Chrastina 2011
This is a descriptive study of the use of a biopsy technique to assist diagnosis of brain
tumours. The study had no control group and it is not eligible for inclusion in the
review as it did not meet study design criteria.
Cianfoni 2007
This is a descriptive article discussing the principles, technique and applications of
brain perfusion CT imaging. It is not eligible for inclusion in the review as it did not
meet study design criteria.
Cote 2017 This is an article discussing the use of MRI for uncomplicated headache. It is noteligible for inclusion in the review as it did not meet study design criteria.
Cowan 1999
This study was of an ineligible intervention (CT scan with and without contrast) and
was also excluded as it was pre-2000, and the review search strategy stated that only
studies published after 2000 would be considered.
Cross 2006
This is a descriptive expert commentary on the referral, diagnosis, and management
of children with epilepsy for surgery. It is not eligible for inclusion in the review as it did
not meet study design criteria.
Daverio 2016
This is a retrospective study exploring process and participant factors associated with
the type of, and timing to neuroimaging in childhood arterial ischaemic stroke in the
emergency department. There was no intervention and the study had no control
group. It is not eligible for inclusion in the review as it did not meet study design
criteria.
Davies 1997
This clinical practice guideline was excluded on study design and also because it was
pre-2000, and the review search strategy stated that only studies published after
2000 would be considered.
Davies 2002
This is a prospective case review looking at infants under one year of age, presenting
to an emergency department after life-threatening events. There was no intervention
or control group. It is not eligible for inclusion in the review as it did not meet study
design criteria.
Davis 2008 This is a review discussing issues around diagnosis in brain tumour studies. It it is noteligible for inclusion in the review as it did not meet study design criteria.
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Dommett 2019
This is a retrospective study assessing clinical pathways for teenagers and young
adults in a regional cancer service. There was no intervention or control group and it
is not eligible for inclusion in the review as it did not meet study design criteria.
Duranovic 2008
This is an article discussing diagnostic procedures in paediatric migraines. There was
no intervention or control group, and it is not eligible for inclusion in the review as it
did not meet study design criteria.
Dutto 2009
This is a before-after study exploring the impact of a clinical pathway, implemented in
2006, on adults presenting to the emergency department with atraumatic headache.
The study compared a time period before the clinical pathway was implemented with
a time period after implementation. It is not a controlled study, and the focus is not on
brain tumours. It is not eligible for inclusion in the review as it did not meet study
design criteria.
ESMO 2007
This is an article outlining clinical recommendations from a guidelines group for
people with malignant glioma. It is not eligible for inclusion in the review as it did not
meet study design criteria.
Faehndrich 2011 This is a review about the use of MRI in space-occupying brain lesions. It is noteligible for inclusion in the review as it did not meet study design criteria.
Ferro 2017
This is a review exploring the diagnosis of epilepsy, treatment of epilepsy, and rare
causes of stroke. There was no intervention or control group, and it is not eligible for
inclusion in the review as it did not meet study design criteria.
Fouke 2015
This is a review and clinical guideline for the role of imaging in the management of
adults with diffuse low-grade glioma. It is not eligible for inclusion in the review as it
did not meet study design criteria.
Fowler 2004 This is a review and clinical guideline for headache in older adults. It is not eligible forinclusion in the review as it did not meet study design criteria.
Frappaz 2003 This is an article outlining recommendations for management of intracranial glioma. Itis not eligible for inclusion in the review as it did not meet study design criteria.
Friedman 2011
This is a review and commentary about the management of people with headache in
the acute care setting. It is not eligible for inclusion in the review as it did not meet
study design criteria.
Furtwangler 2014
This is an article giving an overview of diagnosis and treatment of paediatric
intracranial tumours. It is not eligible for inclusion in the review as it did not meet
study design criteria.
Gago-Veiga 2017
This is an article discussing recommendations of the Spanish Society of Neurology's
Headache Study Group, specifically focusing on the management of people with
secondary headache, and other craniofacial pain, in the emergency department and
primary care. It is not eligible for inclusion in the review as it did not meet study
design criteria.
Gaillard 2011 This is a review and commentary of guidelines for imaging in people with epilepsy. Itis not eligible for inclusion in the review as it did not meet study design criteria.
Gaini 2004a
This is an article discussing the categorisation and diagnostic options for people
presenting with headaches in the emergency department. It is not eligible for inclusion
in the review as it did not meet study design criteria.
Galiano
Fragua 2011
This is a discussion paper, in Spanish, on a protocol for diagnosis and management
of status epilepticus that does not meet the review inclusion criteria. 
Giguere 2012
This is a Cochrane Review looking broadly at the effect of printed educational
materials on professional practice and healthcare outcomes. It is not eligible for
inclusion in the review as it did not meet study design criteria.
Gocan 2016
This is a retrospective data analysis of differences in practice and referral type across
five stroke prevention clinics. It is not a controlled before-after study. It is not eligible
for inclusion in the review as it did not meet study design criteria.
Grant 2017
This conference abstract describes the development of a rapid, GP referral system for
people presenting with headache. The system enables GPs to directly refer people
for diagnostic testing (optometry and CNS imaging). Evaluation of the referral system
was not reported. The report did not meet study inclusion criteria.
Gray 2018
This is a model-based health pre-trial economic assessment of the role of
spectroscopic technology in the diagnosis of brain tumours, explored in primary and
secondary care neuroimaging in the UK and USA. The authors used proof-of-concept
studies and modelling. It is not related to an intervention study. It is not eligible for
inclusion in the review as it did not meet study design criteria.
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Griffiths 2005
This is a case series of adults with localisation-related epilepsy in the UK undergoing
MRI, using the same imaging tool: MR imaging at 3.0 T. There is no control group. It
is not eligible for inclusion in the review as it did not meet study design criteria.
Grooss 2016
This is a population-based cohort study using prospectively collected data from
Danish nationwide registers, to explore the rate of change of general practitioner in
people with and without cancer. It is not eligible for inclusion in the review as it did not
meet study design criteria.
Guilfoyle 2011
This is a retrospective before-after study looking at the management of glioma before
and after the introduction of Improving Outcomes Guidance from NICE UK, in the
Anglian Cancer Network. It was not a controlled study, and it is not eligible for
inclusion in the review as it did not meet study design criteria.
Halperin 1996 This study was excluded as it was pre-2000 and the review search strategy statedthat only studies published after 2000 would be considered.
Handschu 2015
This study used a retrospective survey of 1500 tele-consultations between October
2008 and September 2009, from a large, tele-stroke network in Germany, for people
with and without stroke. It is not eligible for inclusion in the review as it did not meet
study design criteria.
Haneef 2010
This is a before-after study study using referral data from people with temporal lobe
epilepsy, to see if the introduction of a guideline led to change in referral patterns to a
surgical epilepsy centre. It is not eligible for inclusion in the review as there was no
control group and it did not meet study design or participant criteria.
Harada 2007 This is an article discussing the diagnosis of brain lesions and imaging techniques. Itis not eligible for inclusion in the review as it did not meet study design criteria.
Harris 2000
This is a case series looking at whether simple clinical criteria can be usefully applied
to people in the emergency department, to target those most likely to require an
urgent cranial CT scan. It is not eligible for inclusion in the review as it did not meet
study design criteria.
Haswali 2015
This is a discussion paper about American guidelines for neuroimaging of people with
headaches. It is not an intervention study, and it is not eligible for inclusion in the
review as it did not meet study design criteria.
Hatzitolios 2008
This is a retrospective study, using information from 362 elderly people hospitalised at
a stroke centre between 2005 and 2007, to see if their final diagnosis agreed with
initial diagnosis of stroke, on admission. It is not eligible for inclusion in the review as
it did not meet study design or participant criteria.
Jiang 2016 This is a description of a Chinese clinical guideline about adults with diffuse glioma. Itis not eligible for inclusion in the review as it did not meet study design criteria.
Kabbouche 2010
This is a discussion paper about the management of children and adolescents
presenting with headache in an acute setting. It is not eligible for inclusion in the
review as it did not meet study design criteria.
Kahn 2014 This is a review and commentary about the management of headache. It is noteligible for inclusion in the review as it did not meet study design criteria.
Kernick 2009
This is a historical cohort study using data from the UK GP research database for
children aged 5 to 17 years presenting with headache in primary care. The study
compared children with headache to matched controls to explore management, e.g.
number of consultations. It is not eligible for inclusion in the review as it did not meet
study design criteria.
Knox 2012
This is a description of a case series of people admitted to an acute medical unit due
to acute headache, between January and December 2011. The study aimed to better
characterise people referred to acute care with headache, by taking a sample and
looking at investigations undertaken. It is not eligible for inclusion in the review as it
did not meet study design criteria.
Langdon 2017 This is a commentary and overview about paediatric headache. It is not eligible forinclusion in the review as it did not meet study design criteria.
Lange 2011
This is a comparison of the characteristics and diagnoses of people attending the
emergency department with neurological symptoms. There was no intervention, and
the study had no control group. It is not eligible for inclusion in the review as it did not
meet study design criteria.
Langen 2008 This is a review of imaging techniques for people with glioma. It is not eligible forinclusion in the review as it did not meet study design criteria.
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Langen 2011 This is a review and guidance for imaging techniques for people with glioma. It is noteligible for inclusion in the review as it did not meet study design criteria.
Langen 2017 This is a review of neuro-oncology imaging techniques for people with brain tumours.It is not eligible for inclusion in the review as it did not meet study design criteria.
Langen 2018 This is an article giving an update on amino acid PET for brain tumours. It is noteligible for inclusion in the review as it did not meet study design criteria.
Larner 2006 This is a discussion article about referral guidelines for suspected brain tumour. It isnot eligible for inclusion in the review as it did not meet study design criteria.
Laursen 2012
This is a descriptive case series using a local clinical database and retrospective
review of patient records and radiology reports to explore the implementation of the
Integrated Brain Cancer Pathway. There is no control group, and it is not eligible for
inclusion in the review as it did not meet study design criteria.
Laursen 2012a
This is a descriptive case series using a local clinical database and retrospective
review of patient records and radiology reports to explore the implementation of the
Integrated Brain Cancer Pathway. The study looked at the diagnostic process over
eight quarters following the implementation of the pathway. It is not eligible for
inclusion in the review as it did not meet study design criteria.
Le Bas 2005
This is a commentary on the use of perfusion MR imaging in people with brain
tumours. It is not eligible for inclusion in the review as it did not meet study design
criteria.
Leal 2019 This is a discussion about people with acute stroke in the emergency unit. It is noteligible for inclusion in the review as it did not meet study design criteria.
Lee 2018
This abstract describes a retrospective audit examining compliance with the two-week
wait guideline. It is not eligible for inclusion in the review as it did not meet study
design criteria.
Llewellyn 2018
This is a qualitative study of the experiences of people with brain tumours, their
families, and healthcare professionals. It is not eligible for inclusion in the review as it
did not meet study design criteria.
Long 2017
This is a review looking at the management of people with transient ischaemic attack
in the emergency department. It is not eligible for inclusion in the review as it did not
meet study design criteria.
McCrea 2013
This is a commentary using a scenario of new referral to an outpatient clinical, to give
a practical overview of management of children under 5 years of age with headache.
It is not eligible for inclusion in the review as it did not meet study design criteria.
Medina 2002 This is a discussion paper about imaging in paediatric headache. It is not eligible forinclusion in the review as it did not meet study design criteria.
Mirsky 2017
This is an expert consensus on diagnosis and management of suspected stroke in
children. It is not eligible for inclusion in the review as it did not meet study design or
participant criteria.
Mohammad 2016
This is a retrospective study assessing the NICE 'two-week wait' guidelines for CNS
cancer. There is no control group and it is not eligible for inclusion in the review as it
did not meet study design criteria.
Molassiotis 2010
This is a qualitative study of 75 people with cancer, exploring their experience of




This is a retrospective case review of use of MRI versus proton MRI in the
differentiation of brain mass lesions. It is not eligible for inclusion in the review as it
did not meet study design criteria.
Munoz-Ceron
2019
This is an evaluative study of the ICHD-3 criteria for differentiating between primary
and non-primary headaches in all people with headache at a triage unit in an
emergency department. There was no control group. It is not eligible for inclusion in
the review as it did not meet study design criteria.
Nahab 2012
This is a before-after cohort study, comparing before and after the implementation of
an accelerated diagnostic protocol for all people presenting with transient ischaemic
stroke to an emergency department's observation unit, over an 18month period. It
was not a controlled study and it is not eligible for inclusion in the review as it did not
meet study design or participant criteria.
Penfold 2017 This is a discussion article about diagnosing adult primary brain tumours. It is noteligible for inclusion in the review as it did not meet study design criteria.
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Pengiran 2003
This is a case review of people referred to three hospitals, with suspected
neurological cancers, via a two-week wait referral system for brain tumours. There
was no control group and it is not eligible for inclusion in the review as it did not meet
study design criteria.
Pitfield 2012
This is a commentary piece about the management of raised intracranial pressure in
children. It is not eligible for inclusion in the review as it did not meet study design
criteria.
Richards 2009 Not a research study but a supplement bringing together research on England'sNational Awareness and Early Diagnosis Initiative.
Rittman 2012
This is a before-after study assessing the implementation and impact of NICE
guidelines for the referral of any suspected brain tumour to MDT. It was not controlled,
and the focus was not on time-to-diagnosis. It is not eligible for inclusion in the review
as it did not meet study design criteria.
Scharl 2017
Not a study but a German commentary on the European Association for Neuro-
Oncology guideline on the diagnosis and treatment of adult astrocytic and
oligodendroglial gliomas.
Shack 2016
This is a before-after study evaluating whether an institutional acute stroke protocol
could accelerate the diagnosis and secondary treatment of paediatric stroke. It is not




This is a review of the HeadSmart campaign. It is not eligible for inclusion in the
review as it did not meet study design criteria.
Shanmugavadivel
2020
This is a further publication of the HeadSmart study, which did not meet the review
study design criteria, as it lacked a concurrent control group.
Simpson 2010
This is a retrospective study exploring the impact of GP direct-access computerised
tomography for the investigation of chronic daily headache. It is not eligible for
inclusion in the review as it did not meet study design criteria.
Stupp 2009
This is a guideline, clinical recommendation for the management of malignant glioma.
It is not an intervention study, and it is not eligible for inclusion in the review as it did
not meet study design criteria.
Tatencloux 2017
This is a retrospective case review of people under 25 years of age, in Institut Curie,
during one year. It looked at the treatment of children and adolescents, and aimed to
describe care pathways between symptoms and consultation. It is not eligible for
inclusion in the review as it did not meet study design criteria.
Thust 2018
This is a survey, distributed to the European Society of Neuroradiology members
about glioma imaging. It is not eligible for inclusion in the review as it did not meet
study design criteria.
Titlic 2008
This is a test accuracy study of clinical assessment in diagnosing various brain
conditions. It is excluded because it does not meet study design and participant
criteria.
Umotong 2017
This abstract describes a retrospective audit of time from referral for diagnostic
imaging to treatment. It is not eligible for inclusion in the review as it did not meet
study design criteria.
Vedelo 2018 This is a qualitative study of four people with brain tumour, looking at their experience.It is not eligible for inclusion in the review as it did not meet study design criteria.
Walker 2015
This is a conference paper in neuro-oncology, outlining the HeadSmart campaign, as
also detailed in the HeadSmart 2016 paper. It is not eligible for inclusion in the review
as it did not meet study design criteria.
Walker 2016
This is a before-after study exploring the impact of the HeadSmart: Be Brain Tumour
Aware campaign, which was launched in June 2011 across the UK, and aimed to
reduce the total diagnostic interval from a pre-campaign time point in 2006. The study
also sought to improve professional and public awareness of paediatric CNS tumours.
It was not a controlled study, and it is not eligible for inclusion in the review as it did
not meet study design criteria.
Wan 2017
This abstract describes a systematic review examining the impact of hospital and
surgeon characteristics on outcomes for people with brain tumour. It is not eligible for
inclusion in the review as it did not meet study design criteria.
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Webb 2015
This is a retrospective case review of people who had urgent brain cancer referrals to
the neurology service at a British district general hospital, between January 2009 and
September 2013. The study evaluated the brain cancer referral pathway, and sought
to identify the determinants of referrals resulting in significant neurological diagnoses
after specialist review. There was no control group. It is not eligible for inclusion in the
review as it did not meet study design criteria.
Weddell 2017
This abstract describes a retrospective audit examining the time to diagnosis for 50
people. It is not eligible for inclusion in the review as it did not meet study design
criteria.
Weller 2014 This is a guideline for anaplastic glioma and glioblastoma. It is not eligible forinclusion in the review as it did not meet study design criteria.
Weller 2017 This is a guideline, and not a research study. It is not eligible for inclusion in thereview as it did not meet study design criteria.
Williams 2007
This is an audit of radiotherapy dose fractionation, access, and waiting times for
people with cancer in the UK, in 2005. It is not eligible for inclusion in the review as it
did not meet study design criteria.
Wilne 2007 This is a review of presenting symptoms for children with intracranial tumours. It is noteligible for inclusion in the review as it did not meet study design criteria.
Wilne 2010
This is guidance, a review, and results of a Delphi process workshop about referral
and management of children with brain tumours, and recommendations for practice. It
is not eligible for inclusion in the review as it did not meet study design criteria.
Zhou 2018
This is a retrospective analysis of route to diagnosis data for 66,9220 people with 35
cancers, diagnosed between 2006 and 2010, following either fast track or routine
primary to secondary care referral. This was not a controlled study. It is not eligible for
inclusion in the review as it did not meet study design criteria.
Zienius 2019
This retrospective study identified 2938 referrals for direct-access CT scans between
2010 and 2015, to explore the predictive value of the Kernick and NICE 2005 referral
guidelines. It is not eligible for inclusion as it did not meet the study design criteria.
Appendices
Appendix 1. Search strategies
MEDLINE search strategy for effectiveness evidence
1. exp Brain Neoplasms/
 2. ((brain or intracranial or intra-cranial or cerebr*) adj5 (cancer* or tumor* or tumour* or
neoplas* or carcinoma* or metastat* or malignan*)).mp.
 3. (glioma* or astrocytoma* or xanthoastrocytoma* or glioblastoma* or gliosarcoma* or
oligodendrogli* or oligoastrocyt* or ependym* or subependym* or astroblastoma* or
ganglioglioma* or gangliocytoma* or neurocytoma* or liponeurocytoma* or
pineocytoma* or pineoblastoma* or medulloblastoma* or neuroblastoma* or
ganglioneuroblastoma*or medulloepithelioma*).ti,ab.
 4. 1 or 2 or 3
 5. exp Clinical practice guideline/
 6. exp GUIDELINE/
 7. exp Critical Pathways/
 8. ((clinical* or treatment* or diagnos* or practice or critical or care or cancer) adj5
(guideline* or guidance* or pathway*)).ti,ab.
 9. "Clinical Decision-Making"/
 10. (care adj (map* or plan* or interval*)).ti,ab.
 11. Health Planning Guidelines/
 12. Health Plan Implementation/
 13. Public health/
 




16. exp practice guidelines as topic/
17. Health Promotion/
18. Clinical Protocols/
19. exp Consensus Development Conference/
20. (consensus adj3 (develop* or conference*)).mp.
21. 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20
22. exp early diagnosis/
23. "Referral and Consultation"/
24. ((primary or patient or doctor or secondary* or system or total or diagnostic or pre-
diagnostic or treatment or time) adj3 interval*).ti,ab.
25. (cancer waiting time* or total pre-therapy interval* or TPTI).mp.
26. ((direct access* or direct-access* or open access* or open-access* or OACT) adj5
(diagnos* or detect* or interven* or investigat* or refer*)).mp.
27. exp "Diagnostic Techniques and Procedures"/
28. diagnos*.ti,ab.
29. 22 or 23 or 24 or 25 or 26 or 27 or 28
30. 4 and 21 and 29
31. (2000* or 2001* or 2002* or 2003* or 2004* or 2005* or 2006* or 2007* or 2008* or
2009* or 2010* or 2011* or 2012* or 2013* or 2014* or 2015* or 2016* or 2017* or
2018* or 2019* or 2020*).ed.
32. 30 and 31
33. (protocol* adj5 (referral* or algorithm* or strateg* or diagnos*)).mp.
34. 29 and 33
35. exp Stroke/
36. (transient ischaemic attack* or TIA* or stroke* or cerebrovascular accident* or
CVA*).mp.
37. exp Epilepsy/
38. (seizure* or epilep*).mp.
39. exp Headache/
40. ((seizure* or epilep* or transient ischaemic attack* or TIA* or stroke* or
cerebrovascular accident* or CVA* or headache*) adj5 (unexplained or urgent or fast
access or rapid or emergenc* or ED or ER or suspicious or suspect* or "two week wait"
or wait* time or "time to diagnosis" or neurolog* assessment* or scan* or ?imag* or CT
or MRI)).mp.
41. 35 or 36 or 37 or 38 or 39 or 40
42. 34 and 41
43. 32 or 42
key:
mp = title, original title, abstract, name of substance word, subject heading word
pt = publication type
ab = abstract
fs = floating subheading
sh = Medical Subject Heading
The Embase strategy for effectiveness evidence
1. exp brain tumor/
2. ((brain or intracranial or intra-cranial or cerebr*) adj5 (cancer* or tumor* or tumour* or
neoplas* or carcinoma* or metastat* or malignan*)).mp.
3. (glioma* or astrocytoma* or xanthoastrocytoma* or glioblastoma* or gliosarcoma* or
oligodendrogli* or oligoastrocyt* or ependym* or subependym* or astroblastoma* or
ganglioglioma* or gangliocytoma* or neurocytoma* or liponeurocytoma* or
29/10/2020 Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group: Interventions to reduce the time to diagnosis of brain tumours
https://archie.cochrane.org/popups/view.jsp?url=%2Fsections%2Fdocuments%2Fview%3Fversion%3Dz2009041323230151053328358449629%26… 30/59
pineocytoma* or pineoblastoma* or medulloblastoma* or neuroblastoma* or
ganglioneuroblastoma*or medulloepithelioma*).ti,ab.
4. 1 or 2 or 3
5. practice guideline/
6. exp clinical pathway/
7. ((clinical* or treatment* or diagnos* or practice or critical or care or cancer) adj5
(guideline* or guidance* or pathway*)).ti,ab.
8. clinical decision making/
9. (care adj (map* or plan* or interval*)).ti,ab.






16. exp consensus development/
17. (consensus adj3 (develop* or conference*)).mp.
18. 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17
19. exp early diagnosis/
20. "Referral and Consultation"/
21. ((primary or patient or doctor or secondary* or system or total or diagnostic or pre-
diagnostic or treatment or time) adj3 interval*).ti,ab.
22. (cancer waiting time* or total pre-therapy interval* or TPTI).mp.
23. ((direct access* or direct-access* or open access* or open-access* or OACT) adj5
(diagnos* or detect* or interven* or investigat* or refer*)).mp.
24. diagnostic procedure/
25. diagnos*.ti,ab.
26. 19 or 20 or 21 or 22 or 23 or 24 or 25
27. 4 and 18 and 26
28. (2000* or 2001* or 2002* or 2003* or 2004* or 2005* or 2006* or 2007* or 2008* or
2009* or 2010* or 2011* or 2012* or 2013* or 2014* or 2015* or 2016* or 2017* or
2018* or 2019* or 2020*).dd.
29. 27 and 28
30. (protocol* adj5 (referral* or algorithm* or strateg* or diagnos*)).mp.
31. 26 and 30
32. exp cerebrovascular accident/
33. (transient ischaemic attack* or TIA* or stroke* or cerebrovascular accident* or
CVA*).mp.
34. exp epilepsy/
35. (seizure* or epilep*).mp.
36. exp headache/
37. ((seizure* or epilep* or transient ischaemic attack* or TIA* or stroke* or
cerebrovascular accident* or CVA* or headache*) adj5 (unexplained or urgent or fast
access or rapid or emergenc* or ED or ER or suspicious or suspect* or "two week wait"
or wait* time or "time to diagnosis" or neurolog* assessment* or scan* or ?imag* or CT
or MRI)).mp.
38. 32 or 33 or 34 or 35 or 36 or 37
39. 31 and 38
40. 29 or 39
CENTRAL strategy for effectiveness evidence
#1 MeSH descriptor: [Brain Neoplasms] explode all trees
 #2 (brain or intracranial or intra-cranial or cerebr*) near/5 (cancer* or tumor* or tumour*
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or neoplas* or carcinoma* or metastat* or malignan*)
#3 (glioma* or astrocytoma* or xanthoastrocytoma* or glioblastoma* or gliosarcoma* or
oligodendrogli* or oligoastrocyt* or ependym* or subependym* or astroblastoma* or
ganglioglioma* or gangliocytoma* or neurocytoma* or liponeurocytoma* or
pineocytoma* or pineoblastoma* or medulloblastoma* or neuroblastoma* or
ganglioneuroblastoma*or medulloepithelioma*)
#4 #1 or #2 or #3
#5 MeSH descriptor: [Practice Guidelines as Topic] explode all trees
#6 MeSH descriptor: [Critical Pathways] explode all trees
#7 ((clinical* or treatment* or diagnos* or practice or critical or care or cancer) near/5
(guideline* or guidance* or pathway*))
#8 MeSH descriptor: [Clinical Decision-Making] this term only
#9 (care near (map* or plan* or interval*))
#10 MeSH descriptor: [Health Planning Guidelines] this term only
#11 MeSH descriptor: [Health Plan Implementation] this term only
#12 MeSH descriptor: [Public Health] this term only
#13 professional standard
#14 MeSH descriptor: [Guideline Adherence] this term only
#15 MeSH descriptor: [Practice Guidelines as Topic] explode all trees
#16 MeSH descriptor: [Health Promotion] this term only
#17 MeSH descriptor: [Clinical Protocols] this term only
#18 MeSH descriptor: [Consensus Development Conferences as Topic] explode all
trees
#19 (consensus near/3 (develop* or conference*))
#20 #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18
or #19
#21 MeSH descriptor: [Early Diagnosis] explode all trees
#22 MeSH descriptor: [Referral and Consultation] explode all trees
#23 ((primary or patient or doctor or secondary* or system or total or diagnostic or pre-
diagnostic or treatment or time) near/3 interval*)
#24 (cancer waiting time* or total pre-therapy interval* or TPTI)
#25 ((direct access* or direct-access* or open access* or open-access* or OACT)
near/5 (diagnos* or detect* or interven* or investigat* or refer*))
#26 MeSH descriptor: [Diagnostic Techniques and Procedures] this term only
#27 diagnos*
#28 #21 or #22 or #23 or #24 or #25 or #26 or #27
#29 #4 and #20 and #28
#30 MeSH descriptor: [Stroke] explode all trees
#31 transient ischaemic attack* or TIA* or stroke* or cerebrovascular accident* or CVA*
#32 MeSH descriptor: [Epilepsy] explode all trees
#33 seizure* or epilep*
#34 MeSH descriptor: [Headache] explode all trees
#35 headache*
#36 (headache* or seizure* or epilep* or transient ischaemic attack* or TIA* or stroke*
or cerebrovascular accident* or CVA*) near/5 (unexplained or urgent or fast access or
rapid or emergenc* or ED or ER or suspicious or suspect* or "two week wait" or wait*
time or "time to diagnosis" or neurolog* assessment* or scan* or ?imag* or CT or MRI)
#37 #30 or #31 or #32 or #33 or #34 or #35 or #36
#38 protocol* near/5 (referral* or algorithm* or strateg* or diagnos*)
#39 #28 and #38
#40 #39 and #37
#41 #29 or #40
MEDLINE search strategy for economic evidence
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1. exp Brain Neoplasms/
2. ((brain or intracranial or intra-cranial or cerebr*) adj5 (cancer* or tumor* or tumour* or
neoplas* or carcinoma* or metastat* or malignan*)).mp.
3. (glioma* or astrocytoma* or xanthoastrocytoma* or glioblastoma* or gliosarcoma* or
oligodendrogli* or oligoastrocyt* or ependym* or subependym* or astroblastoma* or
ganglioglioma* or gangliocytoma* or neurocytoma* or liponeurocytoma* or
pineocytoma* or pineoblastoma* or medulloblastoma* or neuroblastoma* or
ganglioneuroblastoma*or medulloepithelioma*).ti,ab.
4. 1 or 2 or 3
5. exp Clinical practice guideline/
6. exp GUIDELINE/
7. exp Critical Pathways/
8. ((clinical* or treatment* or diagnos* or practice or critical or care or cancer) adj5
(guideline* or guidance* or pathway*)).ti,ab.
9. "Clinical Decision-Making"/
10. (care adj (map* or plan* or interval*)).ti,ab.
11. Health Planning Guidelines/




16. exp practice guidelines as topic/
17. Health Promotion/
18. Clinical Protocols/
19. exp Consensus Development Conference/
20. (consensus adj3 (develop* or conference*)).mp.
21. 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20
22. exp early diagnosis/
23. "Referral and Consultation"/
24. ((primary or patient or doctor or secondary* or system or total or diagnostic or pre-
diagnostic or treatment or time) adj3 interval*).ti,ab.
25. (cancer waiting time* or total pre-therapy interval* or TPTI).mp.
26. ((direct access* or direct-access* or open access* or open-access* or OACT) adj5
(diagnos* or detect* or interven* or investigat* or refer*)).mp.
27. exp "Diagnostic Techniques and Procedures"/
28. diagnos*.ti,ab.
29. 22 or 23 or 24 or 25 or 26 or 27 or 28
30. 4 and 21 and 29
31. (2000* or 2001* or 2002* or 2003* or 2004* or 2005* or 2006* or 2007* or 2008* or
2009* or 2010* or 2011* or 2012* or 2013* or 2014* or 2015* or 2016* or 2017* or
2018* or 2019* or 2020*).ed.
32. 30 and 31
33. (protocol* adj5 (referral* or algorithm* or strateg* or diagnos*)).mp.
34. 29 and 33
35. exp Stroke/
36. (transient ischaemic attack* or TIA* or stroke* or cerebrovascular accident* or
CVA*).mp.
37. exp Epilepsy/
38. (seizure* or epilep*).mp.
39. exp Headache/
40. ((seizure* or epilep* or transient ischaemic attack* or TIA* or stroke* or
cerebrovascular accident* or CVA* or headache*) adj5 (unexplained or urgent or fast
access or rapid or emergenc* or ED or ER or suspicious or suspect* or "two week wait"
or wait* time or "time to diagnosis" or neurolog* assessment* or scan* or ?imag* or CT
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or MRI)).mp.
41. 35 or 36 or 37 or 38 or 39 or 40
42. 34 and 41
43. 32 or 42
44. economics/
45. exp "costs and cost analysis"/
46. economics, dental/




51. (economic$ or cost or costs or costly or costing or price or prices or pricing or
pharmacoeconomic$).ti,ab.
52. (expenditure$ not energy).ti,ab.
53. (value adj1 money).ti,ab.
54. budget$.ti,ab.
55. 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54
56. ((energy or oxygen) adj cost).ti,ab.
57. (metabolic adj cost).ti,ab.
58. ((energy or oxygen) adj expenditure).ti,ab.
59. 56 or 57 or 58




64. 61 or 62 or 63
65. 60 not 64
66. Animals/
67. Humans/
68. 66 not (66 and 67)
69. 65 not 68
70. 43 and 69
Key
mp=title, abstract, original title, name of substance word, subject heading word,
keyword heading word, protocol supplementary concept word, rare disease




Embase strategy for economic evidence
1. exp brain tumor/
 2. ((brain or intracranial or intra-cranial or cerebr*) adj5 (cancer* or tumor* or tumour* or
neoplas* or carcinoma* or metastat* or malignan*)).mp.
 3. (glioma* or astrocytoma* or xanthoastrocytoma* or glioblastoma* or gliosarcoma* or
oligodendrogli* or oligoastrocyt* or ependym* or subependym* or astroblastoma* or
ganglioglioma* or gangliocytoma* or neurocytoma* or liponeurocytoma* or
pineocytoma* or pineoblastoma* or medulloblastoma* or neuroblastoma* or
ganglioneuroblastoma*or medulloepithelioma*).ti,ab.
 4. 1 or 2 or 3
 5. practice guideline/
 6. exp clinical pathway/
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7. ((clinical* or treatment* or diagnos* or practice or critical or care or cancer) adj5
(guideline* or guidance* or pathway*)).ti,ab.
8. clinical decision making/
9. (care adj (map* or plan* or interval*)).ti,ab.






16. exp consensus development/
17. (consensus adj3 (develop* or conference*)).mp.
18. 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17
19. exp early diagnosis/
20. "Referral and Consultation"/
21. ((primary or patient or doctor or secondary* or system or total or diagnostic or pre-
diagnostic or treatment or time) adj3 interval*).ti,ab.
22. (cancer waiting time* or total pre-therapy interval* or TPTI).mp.
23. ((direct access* or direct-access* or open access* or open-access* or OACT) adj5
(diagnos* or detect* or interven* or investigat* or refer*)).mp.
24. diagnostic procedure/
25. diagnos*.ti,ab.
26. 19 or 20 or 21 or 22 or 23 or 24 or 25
27. 4 and 18 and 26
28. (2000* or 2001* or 2002* or 2003* or 2004* or 2005* or 2006* or 2007* or 2008* or
2009* or 2010* or 2011* or 2012* or 2013* or 2014* or 2015* or 2016* or 2017* or
2018* or 2019* or 2020*).dd.
29. 27 and 28
30. (protocol* adj5 (referral* or algorithm* or strateg* or diagnos*)).mp.
31. 26 and 30
32. exp cerebrovascular accident/
33. (transient ischaemic attack* or TIA* or stroke* or cerebrovascular accident* or
CVA*).mp.
34. exp epilepsy/
35. (seizure* or epilep*).mp.
36. exp headache/
37. ((seizure* or epilep* or transient ischaemic attack* or TIA* or stroke* or
cerebrovascular accident* or CVA* or headache*) adj5 (unexplained or urgent or fast
access or rapid or emergenc* or ED or ER or suspicious or suspect* or "two week wait"
or wait* time or "time to diagnosis" or neurolog* assessment* or scan* or ?imag* or CT
or MRI)).mp.
38. 32 or 33 or 34 or 35 or 36 or 37
39. 31 and 38
40. 29 or 39
41. Health Economics/
42. exp Economic Evaluation/
43. exp Health Care Cost/
44. pharmacoeconomics/
45. 41 or 42 or 43 or 44
46. (econom$ or cost or costs or costly or costing or price or prices or pricing or
pharmacoeconomic$).ti,ab.
47. (expenditure$ not energy).ti,ab.
48. (value adj2 money).ti,ab.
49. budget$.ti,ab.
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50. 46 or 47 or 48 or 49




55. 52 or 53 or 54
56. 51 not 55
57. (metabolic adj cost).ti,ab.
58. ((energy or oxygen) adj cost).ti,ab.
59. ((energy or oxygen) adj expenditure).ti,ab.
60. 57 or 58 or 59
61. 56 not 60
62. 40 and 61
Key
mp=title, abstract, original title, name of substance word, subject heading word,
keyword heading word, protocol supplementary concept word, rare disease




Appendix 2. ‘Risk of bias' assessment of randomised
controlled trials (RCTs)
We will assess the risk of bias of RCTs according to the following criteria.
1. Random sequence generation
Low risk of bias, e.g. participants assigned to treatments on basis of a computer-
generated random sequence or a table of random numbers
High risk of bias, e.g. participants assigned to treatments on basis of date of birth,
clinic identification number or surname, or no attempt to randomise participants
Unclear risk of bias, e.g. not reported, information not available
2. Allocation concealment
Low risk of bias e.g. where the allocation sequence could not be foretold
High risk of bias e.g. allocation sequence could be foretold by patients,
investigators or treatment providers
Unclear risk of bias e.g. not reported
3. Blinding of participants
Low risk of bias if participants were adequately blinded
High risk of bias if participants were not blinded to the intervention that the
participant received
Unclear risk of bias if this was not reported or unclear
4. Blinding of outcomes assessors
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Low risk of bias if outcome assessors were adequately blinded to the intervention
that the participant received
High risk of bias if outcome assessors were not blinded to the intervention that the
participant received
Unclear risk of bias if this was not reported or unclear
5. Incomplete outcome data
We will record the proportion of participants whose outcomes were not reported at the
end of the study. We will code a satisfactory level of loss to follow-up for each outcome
as follows.
Low risk of bias, if fewer than 20% of patients were lost to follow-up and reasons
for loss to follow-up were similar in both treatment arms
High risk of bias, if more than 20% of patients were lost to follow-up or reasons for
loss to follow-up differed between treatment arms
Unclear risk of bias if loss to follow-up was not reported
6. Selective reporting of outcomes
Low risk of bias, e.g. review reports all outcomes specified in the protocol
High risk of bias, e.g. it is suspected that outcomes were selectively reported
Unclear risk of bias, e.g. it is unclear whether outcomes were selectively reported
7. Other bias
Low risk of bias, i.e. no other source of bias suspected, and the trial appears to be
methodologically sound
High risk of bias, if we suspect that the trial was prone to an additional bias
Unclear risk of bias, if we are uncertain whether an additional bias may have been
present
Appendix 3. 'Risk of bias' assessment of non-
randomised studies (NRSs; ROBINS-1)
We will assess the risk of bias of NRSs according to the following criteria. Risk of bias
will be assessed as low, moderate, serious, or critical, depending on the seriousness of
the bias. Where there is insufficient information on which to make a judgement, we will
record 'no information' as the judgement.
1. Possible confounding
We will assess baseline differences, possible post-baseline differences in prognostic
factors, or switching interventions.
2. Bias from participant selection
Both study groups should comprise same representative group being assessed.
3. Bias from classification of interventions
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This relates to differential misclassification of intervention status that is related to the
outcome or the risk of the outcome.
4. Bias due to deviation from interventions or protocol
We will assess whether, and the extent to which deviations from the protocol or
intervention/s allocated occur.
5. Bias due to missing data
We will assess differential loss to follow-up that may relate to prognostic factors.
6. Bias due to outcome measures or outcome assessment
This sort of bias could occur, for example, where outcome assessors are aware of
intervention status, different methods are used to assess the outcome, or measurement
errors are related to intervention status or effects.
7. Bias due to selection of reported results
We will assess how investigators select and report results.
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